Parathyroid carcinoma: Current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics

Oncologist

Volumn 15, Issue 1, 2010, Pages 61-72

  Adam, Mohamed Abdelgadir ^a   Untch, Brian R ^a   Olson Jr , John A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene expression; Intraoperative PTH; Parathyroid carcinoma

Indexed keywords

APP PROTEIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; KCNJ16 PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; TRANSCRIPTOME; TUMOR MARKER; UCHL1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VINCRISTINE;

ACCURACY; ANAMNESIS; CANCER SURGERY; CLINICAL FEATURE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; GENE EXPRESSION; HUMAN; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; KINETICS; LABORATORY TEST; LYMPH NODE DISSECTION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PARATHYROID CARCINOMA; PARATHYROID SCINTISCANNING; PATHOGENESIS; PATIENT MONITORING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT FAILURE; TUMOR BIOPSY; ULTRASOUND;

BIOPSY; DIAGNOSTIC IMAGING; GENE EXPRESSION; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE CARE; MONITORING, PHYSIOLOGIC; MUTATION; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 75649092280     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0185     Document Type: Review

References (86)

1. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485- 493.
2. Hundahl SA, Fleming ID, FremgenAMet al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: A National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86: 538-544.
3. Lee PK, Jarosek SL, Virnig BA et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007;109:1736 -1741.
4. Shane E, Bilezikian JP. Parathyroid carcinoma: A review of 62 patients. Endocr Rev 1982;3:218 -226.
5. Sandelin K, Auer G, Bondeson L et al. Prognostic factors in parathyroid cancer: A review of 95 cases. World J Surg 1992;16:724 -731.
6. Favia G, Lumachi F, Polistina F et al. Parathyroid carcinoma: Sixteen new cases and suggestions for correct management. World J Surg 1998;22: 1225-1230.
7. Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: An update and review. World J Surg 1991;15:738 -744.
8. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600-605.
9. Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: Acollective review. Ann Surg 1969;169:631- 640.
10. Wynne AG, van Heerden J, Carney JA et al. Parathyroid carcinoma: Clinical and pathologic features in 43 patients. Medicine (Baltimore) 1992;71: 197-205.
11. Busaidy NL, Jimenez C, Habra MA et al. Parathyroid carcinoma: A22-year experience. Head Neck 2004;26:716 -726.
12. Kleinpeter KP, Lovato JF, Clark PB et al. Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol 2005;12:260 -266.
13. Hamill J, Maoate K, Beasley SW et al. Familial parathyroid carcinoma in a child. J Paediatr Child Health 2002;38:314 -317.
14. Righi A, Dimosthenous K, Mize J. Mediastinal parathyroid carcinoma with tumor implants in a child: A unique occurrence. Int J Surg Pathol 2008;16: 458-460.
15. Mashburn MA, Chonkich GD, Chase DR et al. Parathyroid carcinoma: Two new cases-diagnosis, therapy, and treatment. Laryngoscope 1987; 97:215-218.
16. Ireland JP, Fleming SJ, Levison DA et al. Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 1985;38:1114 -1118.
17. Miki H, Sumitomo M, Inoue H et al. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 1996;120:897-901.
18. Tominaga Y, Numano M, Uchida K et al. Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in a hemodialysis patient: Report of a case. Surg Today 1995;25:984 -986.
19. Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 1996;5:336 -341.
20. Kelly MD, Sheridan BF, Farnsworth AE et al. Parathyroid carcinoma in a mediastinal sixth parathyroid gland. Aust N Z J Surg 1994;64:446-449.
21. Kameyama K, Takami H. Double parathyroid carcinoma. Endocr J 2003; 50:477- 479.
22. Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 1985;149:522-527.
23. Sandelin K, Tullgren O, Farnebo LO. Clinical course of metastatic parathyroid cancer. World J Surg 1994;18:594 -598; discussion 599.
24. Sandelin K, Thompson NW, Bondeson L. Metastatic parathyroid carcinoma: Dilemmas in management. Surgery 1991;110:978 -986; discussion 986-988.
25. Cryns VL, Thor A, Xu HJ et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-761.
26. Dotzenrath C, Teh BT, Farnebo F et al. Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996;81:3194 -3196.
27. Pearce SH, Trump D, Wooding C et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996;45:195-200.
28. Subramaniam P, Wilkinson S, Shepherd JJ. Inactivation of retinoblastoma gene in malignant parathyroid growths:Acandidate genetic trigger? AustN Z J Surg 1995;65:714 -716.
29. Farnebo F, Auer G, Farnebo LO et al. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 1999;23:68 -74.
30. Shattuck TM, Kim TS, Costa J et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003;59:180 -189.
31. Cryns VL, Rubio MP, Thor AD et al. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994;78:1320 -1324.
32. Haven CJ, van Puijenbroek M, Tan MH et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 2007;67:370 -376.
33. Vasef MA, Brynes RK, SturmMet al. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study. Mod Pathol 1999;12:412- 416.
34. Woodard GE, Lin L, Zhang JH et al. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/ PRAD1 expression. Oncogene 2005;24:1272-1276.
35. Howell VM, Haven CJ, Kahnoski K et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003;40: 657-663.
36. Carpten JD, Robbins CM, Villablanca A et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002;32:676-680.
37. Shattuck TM, Välimäki S, Obara T et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349:1722-1729.
38. Lin L, Zhang JH, Panicker LM et al. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci U S A 2008;105:17420 -17425.
39. Nakajima K, Umino K, Azuma Y et al. Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period. J Bone Miner Metab 2009;27:224 -233.
40. Velázquez-Fernández D, Laurell C, Saqui-SalcesMet al. Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): Primary parathyroid hyperplasia versus adenoma. World J Surg 2006;30:705-713.
41. Forsberg L, Bjorck E, Hashemi J et al. Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology. Eur J Endocrinol 2005;152:459-470.
42. Haven CJ, Howell VM, Eilers PH et al. Gene expression of parathyroid tumors: Molecular subclassification and identification of the potential malignant phenotype. Cancer Res 2004;64:7405-7411.
43. Howell VM, Gill A, Clarkson A et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009;94:434-441.
44. Schoretsanitis G, Daskalakis M, Melissas J et al. Parathyroid carcinoma: Clinical presentation and management. Am J Otolaryngol 2009;30:277-280.
45. Klink BK, Karulf RE, Maimon WN et al. Nonfunctioning parathyroid carcinoma. Am Surg 1991;57:463- 467.
46. Aldinger KA, Hickey RC, Ibanez ML et al. Parathyroid carcinoma: A clinical study of seven cases of functioning and two cases of nonfunctioning parathyroid cancer. Cancer 1982;49:388 -397.
47. Fujimoto Y, Obara T. How to recognize and treat parathyroid carcinoma. Surg Clin North Am 1987;67:343-357.
48. Silverberg SJ, Shane E, Jacobs TP et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990;89:327-334.
49. Laks MS, Kahn SE, Favus MJ et al. Case report: Clinical pathological correlations in a case of primary parathyroid carcinoma. Ann Clin Lab Sci 1984;14:458-463.
50. Hara H, Igarashi A, Yano Y et al. Ultrasonographic features of parathyroid carcinoma. Endocr J 2001;48:213-217.
51. Singhal T, Jacobs M, Mantil JC. Tc-99m pertechnetate/sestamibi subtraction scan in a case of parathyroid carcinoma. Clin Nucl Med 2008;33:196-197.
52. Aigner RM, Fueger GF, Lax S. A case of parathyroid carcinoma visualized on Tc-99m-sestamibi scintigraphy. Nuklearmedizin 1997;36:256 -258.
53. Al-Sobhi S, Ashari LH, Ingemansson S. Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging. Clin Nucl Med 1999;24: 21-23.
54. Clark P, Wooldridge T, Kleinpeter K et al. Providing optimal preoperative localization for recurrent parathyroid carcinoma: A combined parathyroid scintigraphy and computed tomography approach. Clin Nucl Med 2004;29: 681-684.
55. Agarwal G, Dhingra S, Mishra SK et al. Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg 2006;391: 623-626.
56. Spinelli C, Bonadio AG, Berti P et al. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 2000; 23:255-257.
57. Koea JB, Shaw JH. Parathyroid cancer: Biology and management. Surg Oncol 1999;8:155-165.
58. Shortell CK, Andrus CH, Phillips CE Jr et al. Carcinoma of the parathyroid gland: A 30-year experience. Surgery 1991;110:704 -708.
59. Wiseman SM, Rigual NR, Hicks WL Jr et al. Parathyroid carcinoma: A multicenter review of clinicopathologic features and treatment outcomes. Ear Nose Throat J 2004;83:491- 494.
60. Anderson BJ, Samaan NA, Vassilopoulou-Sellin R et al. Parathyroid carcinoma: Features and difficulties in diagnosis and management. Surgery 1983;94:906 -915.
61. Berland Y, Olmer M, Lebreuil G et al. Parathyroid carcinoma, adenoma and hyperplasia in a case of chronic renal insufficiency on dialysis. Clin Nephrol 1982;18:154 -158.
62. Boyle NH, Ogg CS, Hartley RB et al. Parathyroid carcinoma secondary to prolonged hyperplasia in chronic renal failure and in coeliac disease. Eur J Surg Oncol 1999;25:100 -103.
63. Levin KE, Galante M, Clark OH. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 1987;101:649-660.
64. Rattner DW, Marrone GC, Kasdon E et al. Recurrent hyperparathyroidism due to implantation of parathyroid tissue. Am J Surg 1985;149:745-748.
65. Clayman GL, Gonzalez HE, El-Naggar A et al. Parathyroid carcinoma: Evaluation and interdisciplinary management. Cancer 2004;100:900 -905.
66. Vetto JT, Brennan MF, Woodruf J et al. Parathyroid carcinoma: Diagnosis and clinical history. Surgery 1993;114:882- 892.
67. Rathi MS, Ajjan R, Orme SM. A case of parathyroid carcinoma with severe hungry bone syndrome and review of literature. Exp Clin Endocrinol Diabetes 2008;116:487- 490.
68. Chandran M, Deftos LJ, Stuenkel CA et al. Thymic parathyroid carcinoma and postoperative hungry bone syndrome. Endocr Pract 2003;9:152-156.
69. Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: Surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg 2004;28:1287-1292.
70. Clary BM, Garner SC, Leight GS Jr. Intraoperative parathyroid hormone monitoring during parathyroidectomy for secondary hyperparathyroidism. Surgery 1997;122:1034 -1038; discussion 1038-1039.
71. Solórzano CC, Carneiro-Pla DM, Lew JI et al. Intra-operative parathyroid hormone monitoring in patients with parathyroid cancer. Ann Surg Oncol 2007;14:3216 -3222.
72. Untch BR, Barfield ME, Dar M et al. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007;142:1022-1026.
73. Kameyama K, Takami H. Proposal for the histological classification of parathyroid carcinoma. Endocr Pathol 2005;16:49 -52.
74. Fujimoto Y, Obara T, Ito Y et al. Surgical treatment of ten cases of parathyroid carcinoma: Importance of an initial en bloc tumor resection. World J Surg 1984;8:392- 400.
75. Gill AJ, Clarkson A, Gimm O et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidismjaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006;30:1140-1149.
76. Obara T, Okamoto T, Ito Y et al. Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery 1993;114:1040 -1048; discussion 1048-1049.
77. Hoelting T, Weber T, Werner J et al. Surgical treatment of parathyroid carcinoma (review). Oncol Rep 2001;8:931-934.
78. Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3803-3808.
79. Collins MT, Skarulis MC, Bilezikian JP et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-1088.
80. Cohn K, Silverman M, Corrado J et al. Parathyroid carcinoma: The Lahey Clinic experience. Surgery 1985;98:1095-1100.
81. Calandra DB, Chejfec G, Foy BK et al. Parathyroid carcinoma: Biochemical and pathologic response to DTIC. Surgery 1984;96:1132-1137.
82. Yip L, Seethala RR, Nikiforova MN et al. Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery 2008; 144:949 -955; discussion 954-955.
83. Obara T, Fujimoto Y, Kanaji Y et al. Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. Cancer 1990;66:1555-1562.
84. Obara T, Fujimoto Y, Hirayama A et al. Flow cytometric DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer 1990;65:1789 -1793.
85. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNAcytometry in parathyroid carcinoma.AmJ Surg Pathol 1993;17:820-829.
86. Rubin MR, Bilezikian JP, Birken S et al. Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol 2008; 159:469-474.